Compare Harley-Davidson Inc (HOG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Recursion Pharmaceuticals Inc — how do they compare? Harley-Davidson Inc trades at $28.11 (market cap $2.93B), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.53B). The key difference: Harley-Davidson Inc is the larger of the two by market cap, and Harley-Davidson Inc pays a 2.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HOG | RXRX | |
|---|---|---|
Market Cap | $2.93B | $1.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $6.79 |
52-Week Low | $17.19 | $2.84 |
Enterprise Value | $3.32B | $946.50M |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $27.85, up 4.78% today, with a bullish technical signal from moving averages and a neutral RSI near 69. Recent earnings show mixed results, with Q1 2026 missing estimates, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. The company is executing a turnaround strategy, including cost cuts and bringing Revolution Max engine production back to the U.S., amid positive retail sales growth in Q1 2026.
The outlook is cautious; while valuation ratios like P/E of 13.77 and P/B of 0.91 appear attractive, declining revenue and net income margins pose risks. Analyst consensus is mostly Hold (65.71%), with a price target of $23.40 below the current price, indicating skepticism about near-term growth despite operational initiatives.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
